These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 33747195)

  • 1. BRAP2 inhibits the Ras/Raf/MEK and PI3K/Akt pathways in leukemia cells, thereby inducing apoptosis and inhibiting cell growth.
    Sakai H; Shiina I; Shinomiya T; Nagahara Y
    Exp Ther Med; 2021 May; 21(5):463. PubMed ID: 33747195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways.
    Su CC
    Oncol Rep; 2018 Nov; 40(5):3102-3111. PubMed ID: 30226540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells.
    Shelton JG; Steelman LS; Lee JT; Knapp SL; Blalock WL; Moye PW; Franklin RA; Pohnert SC; Mirza AM; McMahon M; McCubrey JA
    Oncogene; 2003 Apr; 22(16):2478-92. PubMed ID: 12717425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
    Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA
    Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy.
    Li Q; Li Z; Luo T; Shi H
    Mol Biomed; 2022 Dec; 3(1):47. PubMed ID: 36539659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation.
    Shelton JG; Moye PW; Steelman LS; Blalock WL; Lee JT; Franklin RA; McMahon M; McCubrey JA
    Leukemia; 2003 Sep; 17(9):1765-82. PubMed ID: 12970777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
    Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
    Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-34a/c induce caprine endometrial epithelial cell apoptosis by regulating circ-8073/CEP55 via the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways.
    Liu X; Zhang L; Yang L; Cui J; Che S; Liu Y; Han J; An X; Cao B; Song Y
    J Cell Physiol; 2020 Dec; 235(12):10051-10067. PubMed ID: 32474960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
    Shingu T; Holmes L; Henry V; Wang Q; Latha K; Gururaj AE; Gibson LA; Doucette T; Lang FF; Rao G; Yuan L; Sulman EP; Farrell NP; Priebe W; Hess KR; Wang YA; Hu J; Bögler O
    J Transl Med; 2016 Feb; 14():46. PubMed ID: 26861698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
    Asati V; Mahapatra DK; Bharti SK
    Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals.
    von Gise A; Lorenz P; Wellbrock C; Hemmings B; Berberich-Siebelt F; Rapp UR; Troppmair J
    Mol Cell Biol; 2001 Apr; 21(7):2324-36. PubMed ID: 11259582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
    Canté-Barrett K; Spijkers-Hagelstein JA; Buijs-Gladdines JG; Uitdehaag JC; Smits WK; van der Zwet J; Buijsman RC; Zaman GJ; Pieters R; Meijerink JP
    Leukemia; 2016 Sep; 30(9):1832-43. PubMed ID: 27174491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.
    Steelman LS; Abrams SL; Whelan J; Bertrand FE; Ludwig DE; Bäsecke J; Libra M; Stivala F; Milella M; Tafuri A; Lunghi P; Bonati A; Martelli AM; McCubrey JA
    Leukemia; 2008 Apr; 22(4):686-707. PubMed ID: 18337767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer.
    Choi C; Kwon J; Lim S; Helfman DM
    Oncotarget; 2016 Sep; 7(39):63466-63487. PubMed ID: 27563827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.
    Müller E; Bauer S; Stühmer T; Mottok A; Scholz CJ; Steinbrunn T; Brünnert D; Brandl A; Schraud H; Kreßmann S; Beilhack A; Rosenwald A; Bargou RC; Chatterjee M
    Leukemia; 2017 Apr; 31(4):922-933. PubMed ID: 27686868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-leukemia effect of perillyl alcohol in Bcr/Abl-transformed cells indirectly inhibits signaling through Mek in a Ras- and Raf-independent fashion.
    Clark SS; Zhong L; Filiault D; Perman S; Ren Z; Gould M; Yang X
    Clin Cancer Res; 2003 Oct; 9(12):4494-504. PubMed ID: 14555523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.